Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials

A Bayas, M Christ, S Faissner… - Therapeutic …, 2023 - journals.sagepub.com
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

[PDF][PDF] Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical …

A Bayas, M Christ, S Faissner, J Klehmet, R Pul… - 2023 - opus.bibliothek.uni-augsburg.de
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis –
a review of population-specific ev Page 1 https://doi.org/10.1177/17562864221146836 https://doi.org/10.1177/17562864221146836 …

[PDF][PDF] Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical …

A Bayas, M Christ, S Faissner, J Klehmet, R Pul - 2023 - pdfs.semanticscholar.org
Disease-modifying therapies for relapsing/ active secondary progressive multiple sclerosis
– a review of population-specific e Page 1 https://doi.org/10.1177/17562864221146836 …

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis-a review of population-specific evidence from randomized clinical trials.

A Bayas, M Christ, S Faissner, J Klehmet… - Therapeutic …, 2023 - europepmc.org
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis-a review of population-specific evidence from randomized clinical trials

A Bayas, M Christ, S Faissner… - Therapeutic …, 2023 - pubmed.ncbi.nlm.nih.gov
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

[PDF][PDF] Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical …

A Bayas, M Christ, S Faissner, J Klehmet, R Pul - 2023 - d-nb.info
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis –
a review of population-specific ev Page 1 https://doi.org/10.1177/17562864221146836 https://doi.org/10.1177/17562864221146836 …

[HTML][HTML] Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical …

A Bayas, M Christ, S Faissner, J Klehmet… - Therapeutic …, 2023 - ncbi.nlm.nih.gov
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials

A Bayas, M Christ, S Faissner, J Klehmet, R Pul - 2023 - europepmc.org
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …